Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.
暂无分享,去创建一个
M. Duffy | C. Haglund | R. Klapdor | R. Lamerz | C. Sturgeon | O. Topolcan | V. Heinemann | C. Haglund | A. Nicolini | M. Duffy | C. Sturgeon | V. Holubec
[1] D. Goldstein,et al. WITHDRAWN: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. , 2009, The Cochrane database of systematic reviews.
[2] D. Goldstein,et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. , 2009, The Cochrane database of systematic reviews.
[3] J. Disario,et al. Improved Diagnosis of Pancreatic Adenocarcinoma Using Haptoglobin and Serum Amyloid A in a Panel Screen , 2009, World Journal of Surgery.
[4] C. Haglund,et al. Comparison of three immunoassays for CA 19-9. , 2009, Clinica chimica acta; international journal of clinical chemistry.
[5] R. Abrams,et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[7] L. Liotta,et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. , 2008, Clinical chemistry.
[8] M. Grossbard,et al. Metastatic pancreatic cancer 2008: is the glass less empty? , 2008, The oncologist.
[9] Douglas B. Evans,et al. Tumor‐Node‐Metastasis Staging of Pancreatic Adenocarcinoma , 2008, CA: a cancer journal for clinicians.
[10] S. Chari,et al. Microarray Technologies for Gene Transcript Analysis in Pancreatic Cancer , 2008, Technology in cancer research & treatment.
[11] A. Siriwardena,et al. Current status of gene expression profiling of pancreatic cancer. , 2008, International journal of surgery.
[12] W. Scheithauer,et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. , 2008, The Lancet. Oncology.
[13] Y. Gong,et al. Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound‐guided fine‐needle aspiration specimens of the pancreas , 2007, International journal of cancer.
[14] R. Labianca,et al. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] J. Manson,et al. Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. , 2007, Cancer research.
[16] M. Pino,et al. Gemcitabine‐based combinations for inoperable pancreatic cancer: Have we made real progress? , 2007, Cancer.
[17] K. Gurusamy,et al. Tumor M2-Pyruvate Kinase as Tumor Marker in Exocrine Pancreatic Cancer A Meta-Analysis , 2007, Pancreas.
[18] Eithne Costello,et al. Biology and management of pancreatic cancer , 2007, Postgraduate Medical Journal.
[19] E. Wiemer. The role of microRNAs in cancer: no small matter. , 2007, European journal of cancer.
[20] Catrin Tudur Smith,et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Tao Peng,et al. Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers. , 2007, Biochimica et biophysica acta.
[22] J. Manson,et al. Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts , 2007, British Journal of Cancer.
[23] C. Croce,et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. , 2007, JAMA.
[24] M. Duffy. Role of tumor markers in patients with solid cancers: A critical review. , 2007, European journal of internal medicine.
[25] A. Siriwardena,et al. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[26] W. Roberts,et al. Performance characteristics of five automated CA 19-9 assays. , 2007, American journal of clinical pathology.
[27] A. Benson. Adjuvant therapy for pancreatic cancer: one small step forward. , 2007, JAMA.
[28] Thomas D. Schmittgen,et al. Expression profiling identifies microRNA signature in pancreatic cancer , 2006, International journal of cancer.
[29] Daniel F Hayes,et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Ferlay,et al. Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] V. Heinemann,et al. Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer , 2006, Oncology.
[32] E. Małecka-Panas,et al. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. , 2006, Medical science monitor : international medical journal of experimental and clinical research.
[33] E. Urgell,et al. Agreement between K-ras sequence variations detected in plasma and tissue DNA in pancreatic and colorectal cancer. , 2006, Clinical chemistry.
[34] D. Finkelstein,et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] A. Jimeno,et al. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer , 2006, Molecular Cancer Therapeutics.
[36] D. Chan,et al. Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9 , 2006, Clinical Cancer Research.
[37] N. Scarmeas,et al. CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer , 2005, Journal of Gastrointestinal Surgery.
[38] C P Neal,et al. Molecular prognostic markers in pancreatic cancer: a systematic review. , 2005, European journal of cancer.
[39] A. Mills. p53: link to the past, bridge to the future. , 2005, Genes & development.
[40] M. Goggins. Molecular markers of early pancreatic cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] M. Tempero,et al. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer , 2005, British Journal of Cancer.
[42] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[43] N. Teich,et al. Molecular Analysis of Pancreatic Juice: A Helpful Tool to Differentiate Benign and Malignant Pancreatic Tumors? , 2005, Digestive Diseases.
[44] C. Haglund,et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry , 2005, Gut.
[45] H. Oettle,et al. Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes , 2005, British Journal of Cancer.
[46] S. Batra,et al. Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy , 2004, British Journal of Cancer.
[47] K. Kinzler,et al. Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers , 2004, Clinical Cancer Research.
[48] De-qing Mu,et al. Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience. , 2004, World journal of gastroenterology.
[49] T. Sauerbruch,et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine , 2003, British Journal of Cancer.
[50] M. Barbacid,et al. RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.
[51] E. Saad,et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine , 2002, International journal of gastrointestinal cancer.
[52] C. Haglund,et al. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. , 2002, Anticancer research.
[53] J. Levine,et al. Surfing the p53 network , 2000, Nature.
[54] V. Keim,et al. Decrease of CA 19–9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer , 2000, British Journal of Cancer.
[55] R. Lamerz,et al. Tumour markers in prostate cancer: EGTM recommendations , 1999 .
[56] E. Köttgen,et al. K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases. , 1998, Clinical chemistry.
[57] M. Duffy. CA 19-9 as a Marker for Gastrointestinal Cancers: A Review , 1998, Annals of clinical biochemistry.
[58] J. Robertson,et al. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma , 1996, Cancer.
[59] F. Galeotti,et al. Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation. , 1996, Anticancer research.
[60] K. Partanen,et al. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy. , 1995, Anticancer research.
[61] W. Steinberg. The clinical utility of the CA 19-9 tumor-associated antigen. , 1990, The American journal of gastroenterology.
[62] W. Steinberg,et al. Elevated serum levels of tumor marker CA19-9 in acute cholangitis , 1988, Digestive Diseases and Sciences.
[63] M. Tempero,et al. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. , 1988, Cancer research.
[64] S. Itzkowitz,et al. New carbohydrate tumor markers. , 1986, Gastroenterology.
[65] A. Jemal,et al. Global Cancer Statistics , 2011 .
[66] E. Nakakura,et al. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.
[67] Michael A. Hollingsworth,et al. Mucins in cancer: protection and control of the cell surface , 2004, Nature Reviews Cancer.
[68] R. Lamerz. Role of tumour markers, cytogenetics. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[69] Quality requirements and control: EGTM recommendations. European Group on Tumour Markers. , 1999, Anticancer research.
[70] T. Ørntoft,et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. , 1999, Clinical chemistry.